Related Experiment Video
Updated: May 29, 2026
07:47
Experimental Human Pneumococcal Carriage
Published on: February 15, 2013
13-valent pneumococcal conjugate vaccine (PCV13)
Johanna M C Jefferies1, Emily Macdonald, Saul N Faust
1Faculty of Medicine, University of Southampton, Southampton, UK.
Human Vaccines
|September 24, 2011
Summary
The thirteen valent pneumococcal conjugate vaccine (PCV13) offers broader protection than PCV7, addressing persistent pneumococcal disease threats. PCV13 demonstrates comparable safety and efficacy, expanding global immunization coverage.
Area of Science:
- Vaccinology
- Infectious Diseases
- Public Health
Background:
- Pneumococcal conjugate vaccines (PCV7) significantly reduced pneumococcal disease but did not cover all serotypes.
- Non-PCV7 serotypes, particularly 1, 5, and 19A, remain a threat, especially in developing countries.
- Increasing incidence of disease due to specific non-PCV7 serotypes has been observed in PCV7-vaccinated populations.
Purpose of the Study:
- To review the literature on the thirteen valent pneumococcal conjugate vaccine (PCV13).
- To describe the safety, efficacy, global serotype coverage, and use of PCV13.
- To discuss future directions for PCV13 in global immunization strategies.
Main Methods:
- Review of current scientific literature on PCV13.
- Analysis of data from non-inferiority trials for PCV13 licensing.
- Examination of global serotype coverage and vaccine rollout data.
Main Results:
- PCV13 includes thirteen pneumococcal serotypes, expanding coverage beyond PCV7.
- PCV13 has been licensed based on non-inferiority trials, demonstrating comparable safety and efficacy to PCV7.
- PCV13 replaced PCV7 in childhood immunization schedules in the USA and UK in 2010 and is being introduced globally.
Conclusions:
- PCV13 represents a significant advancement in pneumococcal conjugate vaccination.
- The vaccine offers broader serotype coverage, addressing limitations of PCV7.
- PCV13 is poised to improve global control of pneumococcal disease, particularly in high-burden regions.
Related Concept Videos
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:30Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
01:30Cancer Vaccines
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Streptococcal Pharyngitis
Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
01:30Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...